Uniseed is a venture capital firm founded in 2000 and based in Saint Lucia, Australia. Established as a joint initiative between the University of Melbourne and the University of Queensland, Uniseed focuses on investing in technology start-ups, particularly those emerging from its partner research organizations. The firm operates through multiple funds, with its latest, launched in 2015, involving the University of Sydney and CSIRO alongside its founding partners. Uniseed's investment strategy emphasizes long-term partnerships with academic institutions, providing tailored commercialization services that enhance their capabilities. The firm has made over 20 investments, typically ranging from $250,000 to $2.5 million, and has a track record of successful exits. Uniseed's commitment to supporting research commercialization is underscored by its significant contributions to the research ecosystem, which includes nearly $4 billion in research spending and numerous invention disclosures. The firm prioritizes a balanced approach to measuring success, focusing on financial returns, the establishment of viable start-ups, and the enhancement of commercialization processes for its partners.
Investment Director, Technology and Member of Investment Committee
Peter Devine
CEO
Laura Droessler-Dansie
Investment Manager
John Kurek
Investment Director
Anthony Musumeci
Investment Manager
Liza Yeo
Investment Manager, Biotechnology and Member of Investment Committee
Past deals in Australasia
Aravax
Series B in 2024
Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergies. Founded in May 2015 through the acquisition of intellectual property from Alfred Health and Monash University, Aravax employs proprietary technology aimed at resetting the immune system to tolerate peanuts without triggering allergic reactions. The company's innovative approach seeks to eliminate the risk of life-threatening responses to peanuts, allowing patients to undergo treatment and potentially overcome mild symptoms such as itchiness, rash, and gastrointestinal upset.
Morse Micro
Series B in 2022
Morse Micro is a wireless integrated circuit solutions company focused on reinventing Wi-Fi for the Internet of Things (IoT). Founded by industry experts including Wi-Fi pioneers, the company is headquartered in Australia with additional offices in China and the United States. Morse Micro specializes in low-power wireless chips that enhance Wi-Fi connectivity across a wide range of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. Their innovative technology allows for smaller and more cost-effective chips, facilitating a robust IoT ecosystem that supports connected devices operating over greater distances. The company's diverse team and strong portfolio of intellectual property position it as a key player in the evolving IoT market.
Tiny Bright Things
Seed Round in 2022
Tiny Bright Things is a Melbourne-based company founded in 2020 by Ray Dagastine and Chris Bolton, specializing in innovative microscopy technology known as Halo microscopy. This technology significantly enhances the imaging and measurement of small or transparent objects, catering to the needs of industrial manufacturers and researchers across various fields. In particular, it serves sectors such as agrichemicals and pharmaceuticals, where the size and shape of powders are crucial. Additionally, the technology is instrumental in nanotechnology and life sciences, enabling accurate analysis of samples that are often tiny or transparent. By allowing imaging and measurement down to the scale of viruses, drug particles, and nanotubes without altering the samples, Tiny Bright Things supports effective research and development at various stages of discovery.
OccuRx
Series B in 2022
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014, focusing on the development of innovative therapeutic strategies for ophthalmic disorders linked to retinal fibrosis. The company aims to address the unmet clinical need for targeted ocular therapies through its proprietary small-molecule drugs, which are designed to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases. OccuRx's strategies enable healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation in the retina, thereby improving patient outcomes in the treatment of these conditions.
Morse Micro
Series B in 2022
Morse Micro is a wireless integrated circuit solutions company focused on reinventing Wi-Fi for the Internet of Things (IoT). Founded by industry experts including Wi-Fi pioneers, the company is headquartered in Australia with additional offices in China and the United States. Morse Micro specializes in low-power wireless chips that enhance Wi-Fi connectivity across a wide range of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. Their innovative technology allows for smaller and more cost-effective chips, facilitating a robust IoT ecosystem that supports connected devices operating over greater distances. The company's diverse team and strong portfolio of intellectual property position it as a key player in the evolving IoT market.
Forcite Helmet Systems
Series A in 2022
Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in manufacturing smart helmets designed to enhance motorcycle safety. These helmets feature an integrated camera system, navigation, intercom, and active noise-cancelling technology, aiming to address the safety gaps commonly associated with motorcycling. By leveraging advanced sensor technology and the Forcite Command software platform, the company seeks to make motorcycling significantly safer compared to traditional helmets. The lightweight carbon fiber construction of the helmets further contributes to their innovative design. Forcite is committed to improving the riding experience through its cutting-edge helmet solutions.
Ena Respiratory
Venture Round in 2021
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.
Ena Respiratory
Venture Round in 2021
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.
Kinoxis Therapeutics
Series A in 2020
Kinoxis Therapeutics is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstrating potent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing.
Ena Respiratory
Series A in 2020
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.
Wildlife Drones
Venture Round in 2019
Wildlife Drones Pty. Ltd., founded in 2016 and headquartered in Macquarie, Australia, specializes in the design and development of innovative animal radio-tracking systems using drone technology. With over 25 years of experience in ecological and scientific research, the company addresses the challenges associated with tracking highly mobile animals. Traditional ground-based radio-tracking methods often require significant effort to achieve clear signals, which can be costly and labor-intensive. By utilizing drones, Wildlife Drones enhances the altitude from which data is collected, significantly improving the quality and quantity of radio-tracking information. This technology enables wildlife researchers, conservationists, and environmental consultants to effectively monitor endangered species, track invasive species, and locate livestock on remote properties, ultimately aiding in the prevention and mitigation of environmental damage.
Aurtra
Seed Round in 2019
Aurtra delivers highly cost-effective asset management solutions for power distribution transformers through online condition monitoring and state of the art analysis.They provide the insight to significantly reduce capital costs through maximum asset utilisation. Aurtra is an Australian company, based in sunny Brisbane, Australia. Aurtra was incorporated in 2016 and has built its IP upon a foundation of world’s best practice technology from The University of Queensland, following a decade of transformer research between academia and industry. Aurtra’s three founders, all with success commercialising hardware and software technology, recognised the potential of the technology and its beneficial impact for asset management in the power distribution industry.
Morse Micro
Series A in 2019
Morse Micro is a wireless integrated circuit solutions company focused on reinventing Wi-Fi for the Internet of Things (IoT). Founded by industry experts including Wi-Fi pioneers, the company is headquartered in Australia with additional offices in China and the United States. Morse Micro specializes in low-power wireless chips that enhance Wi-Fi connectivity across a wide range of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. Their innovative technology allows for smaller and more cost-effective chips, facilitating a robust IoT ecosystem that supports connected devices operating over greater distances. The company's diverse team and strong portfolio of intellectual property position it as a key player in the evolving IoT market.
Agerris
Seed Round in 2019
Agerris is a field robotics and artificial intelligence start-up focused on enhancing the agricultural sector. Originating from technology developed at the Australian Centre for Field Robotics at the University of Sydney, Agerris has been creating innovative ground and air robotic solutions since 2005. The company specializes in using proprietary artificial intelligence to integrate mapping and decision-making systems into its robotic systems. These advanced technologies enable the detection of weeds, counting of fruits, nuts, crops, and animals, as well as providing comprehensive assessments of crops, livestock, and environmental conditions. By improving farm productivity, Agerris aims to contribute to both environmental sustainability and animal welfare in agriculture.
Forcite Helmet Systems
Seed Round in 2019
Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in manufacturing smart helmets designed to enhance motorcycle safety. These helmets feature an integrated camera system, navigation, intercom, and active noise-cancelling technology, aiming to address the safety gaps commonly associated with motorcycling. By leveraging advanced sensor technology and the Forcite Command software platform, the company seeks to make motorcycling significantly safer compared to traditional helmets. The lightweight carbon fiber construction of the helmets further contributes to their innovative design. Forcite is committed to improving the riding experience through its cutting-edge helmet solutions.
Wildlife Drones
Seed Round in 2019
Wildlife Drones Pty. Ltd., founded in 2016 and headquartered in Macquarie, Australia, specializes in the design and development of innovative animal radio-tracking systems using drone technology. With over 25 years of experience in ecological and scientific research, the company addresses the challenges associated with tracking highly mobile animals. Traditional ground-based radio-tracking methods often require significant effort to achieve clear signals, which can be costly and labor-intensive. By utilizing drones, Wildlife Drones enhances the altitude from which data is collected, significantly improving the quality and quantity of radio-tracking information. This technology enables wildlife researchers, conservationists, and environmental consultants to effectively monitor endangered species, track invasive species, and locate livestock on remote properties, ultimately aiding in the prevention and mitigation of environmental damage.
Q-Sera
Venture Round in 2018
Q-Sera Pty Ltd specializes in developing innovative blood collection tubes that enhance the efficiency of blood clotting, utilizing snake venom-derived proteins. This technology accelerates the clotting process, allowing for the rapid production of high-quality serum essential for biochemical analysis and clinical diagnostics. The company's approach leverages potent prothrombin activators isolated from the venom of certain snakes, including the Australian Taipan. These proteins are manufactured through modified cell lines using standard pharmaceutical processes, ensuring reliability and effectiveness. By improving the speed and quality of serum production, Q-Sera's technology aims to optimize laboratory efficiency and enhance patient care.
Kinoxis Therapeutics
Seed Round in 2018
Kinoxis Therapeutics is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstrating potent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing.
Kinoxis Therapeutics
Venture Round in 2018
Kinoxis Therapeutics is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstrating potent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing.
Brisbane Materials
Series B in 2017
Brisbane Materials Technology Pty Ltd., founded in 2005 and based in St Lucia, Australia, specializes in the manufacturing of anti-reflective coatings for various applications, notably in lighting and solar power. The company emerged from the University of Queensland and has benefited from significant investment in technology and application expertise over the years. Brisbane Materials focuses on producing innovative, low-cost optical coatings, such as porous silica-based anti-reflective coatings, using a patented synthesis process that operates at room temperature and atmospheric pressure. This technology not only enhances the efficiency of solar panel covers, both photovoltaic and solar thermal, but also provides cost-effective solutions for lighting applications. As a subsidiary of XeroCoat, Inc., Brisbane Materials aims to expand its offerings by applying its unique coatings across a broader range of materials and applications.
Ena Respiratory
Venture Round in 2017
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.
Smart Sparrow
Series C in 2017
Smart Sparrow operates an innovative e-learning platform that allows educators and organizations to create interactive and adaptive courseware across various subjects, such as digital literacy, computer science, engineering, finance, and soft skills. Founded in December 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. The platform features a user-friendly, drag-and-drop authoring tool accessible through any web browser, enabling educators to build customized courses, define personalized learning paths for students, and collaborate in real-time. Additionally, Smart Sparrow provides pre-made templates to streamline the course creation process, serving a diverse range of institutions both locally and internationally.
OccuRx
Venture Round in 2015
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014, focusing on the development of innovative therapeutic strategies for ophthalmic disorders linked to retinal fibrosis. The company aims to address the unmet clinical need for targeted ocular therapies through its proprietary small-molecule drugs, which are designed to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases. OccuRx's strategies enable healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation in the retina, thereby improving patient outcomes in the treatment of these conditions.
Spinifex Pharmaceuticals
Series C in 2014
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech
Venture Round in 2013
Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.
Hydrexia
Series B in 2013
Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.
Hatchtech
Venture Round in 2012
Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.
Spinifex Pharmaceuticals
Series B in 2011
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Verva Pharmaceuticals
Venture Round in 2011
Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
Smart Sparrow
Series A in 2011
Smart Sparrow operates an innovative e-learning platform that allows educators and organizations to create interactive and adaptive courseware across various subjects, such as digital literacy, computer science, engineering, finance, and soft skills. Founded in December 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. The platform features a user-friendly, drag-and-drop authoring tool accessible through any web browser, enabling educators to build customized courses, define personalized learning paths for students, and collaborate in real-time. Additionally, Smart Sparrow provides pre-made templates to streamline the course creation process, serving a diverse range of institutions both locally and internationally.
Otifex
Series A in 2010
Otifex Therapeutics Pty Ltd is an emerging Australian specialty pharmaceutical company developing a new treatment for the most common cause of acquired hearing loss in childhood, Otitis Media with Effusion (OME or “glue ear”). Treating OME often means surgically inserting “grommets” (tympanostomy tubes) to help return middle ear pressure to normal; there are currently no non-invasive alternatives. Otifex is developing a novel nasal spray to make it easier for the ears to ‘pop’, improving middle ear pressure and helping OME resolve naturally. Our product has the potential to be the first effective non-surgical treatment for OME.
Hatchtech
Venture Round in 2010
Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.
Manjrasoft
Venture Round in 2009
Manjrasoft Pty. Ltd. commercializes the grid and cloud computing software technologies developed by the Grid Computing and Distributed Systems Laboratory. It provides Aneka, a development and management platform with rapid application development and workload distribution capabilities; Aneka for distributed 3D rendering using Autodesk Maya; Aneka for education and training; Aneka design explorer tool, which is used to build a solution to accelerate 3D rendering; and build, accelerate, and manage services. The company serves engineering, entertainment and gaming, life sciences, and finance markets. Manjrasoft Pty. Ltd. was founded in 2008 and is headquartered in Melbourne, Australia.
Verva Pharmaceuticals
Venture Round in 2009
Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
Fibrotech Therapeutics
Series A in 2008
Fibrotech Therapeutics focuses on developing innovative drug candidates aimed at treating fibrosis related to various chronic conditions. The company's research and development efforts are directed towards addressing diseases such as diabetic nephropathy, kidney diseases, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006 and based in Wonga Park, Australia, Fibrotech Therapeutics is dedicated to improving patient outcomes through its targeted therapeutic solutions.
Spinifex Pharmaceuticals
Series A in 2008
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
OPAL Therapeutics
Series A in 2005
OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.
Spinifex Pharmaceuticals
Series A in 2005
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech
Venture Round in 2005
Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.
QRxPharma
Series A in 2002
QRxPharma Limited is an Australian pharmaceutical company focused on the research, development, and commercialization of biopharmaceutical products primarily in pain management and abuse prevention. The company is known for its Dual Opioid platform technology, which features a patented combination of morphine and oxycodone aimed at enhancing pain relief. Additionally, QRxPharma has developed Stealth Beadlets™, a proprietary technology designed to prevent drug abuse by incorporating deterrent features into solid dosage forms. The company has strategic agreements with various partners for the commercialization of its lead product candidate, immediate release MOXDUO®, which is intended for the treatment of acute pain. QRxPharma's clinical pipeline includes both intravenous and controlled release formulations of MOXDUO. Although QRxPharma does not currently have significant operations, it continues to pursue the development of its product portfolio aimed at improving patient outcomes and reducing risks associated with pain management therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.